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Abstract
Progestogens (vaginal progesterone and intramuscular 17-hydroxyprogesterone ace-
tate) are widely recommended for women at high risk of preterm birth. Typical regimens 
include 17-hydroxyprogesterone caproate (250 mg intramuscularly weekly), starting at 
16–20 gestational weeks until 36 weeks or delivery for women with a singleton gesta-
tion and a history of spontaneous preterm birth, or vaginal progesterone (90-mg vaginal 
gel or 200-mg micronized vaginal soft capsules) for women with a short cervix (typically 
≤25 mm). Although some randomized trials support this approach, neither of the largest 
trials (PROLONG for 17-hydroxyprogesterone acetate or OPPTIMUM for vaginal pro-
gesterone) demonstrated efficacy. There are almost no data on long-term effects, and 
none that shows benefit beyond the neonatal period. Although some analyses suggest 
the cost-effectiveness of the approach, a cervical length screening program followed by 
progesterone for those with a short cervix will reduce preterm birth rates by less than 
0.5%. The present review assesses evidence on the efficacy, likely impact, and long-
term effects of implementing the recommendations for progestogens in full. Clinicians 
and pregnant women can look forward to resolution of the conflicting views on efficacy 
once the Patient-Centered Outcomes Research Initiative (PCORI)-funded individual 
patient data meta-analysis is published.
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1  | BACKGROUND
The importance of progesterone in the maintenance of pregnancy is 
well established and applies across many species. Indeed, the term 
“progesterone” is derived from the phrase “progestational steroidal 
ketone.” In 2015, the International Federation of Gynecology and 
Obstetrics (FIGO) working group on the best practice in mater-
nal fetal medicine published a guideline endorsing the use of pro-
gesterone to prevent preterm birth for selected women.1 The 
guideline states:
• “Sonographic cervical length measurement should be performed 
in all pregnant patients at 19–236 weeks of gestation using 
transvaginal ultrasound. This can be done at the same time as the 
ultrasound performed for the anatomical survey (Fig. 1).”
• “Women with a sonographic short cervix (≤25 mm) diagnosed in the 
mid-trimester should be offered daily vaginal micronized progesterone 
treatment for the prevention of preterm birth and neonatal morbidity.”
• “The progesterone formulation to be used is vaginal micronized 
progesterone (200-mg vaginal soft capsules) nightly or vaginal 
micronized progesterone gel (90 mg) each morning.”
• “Universal cervical length screening and vaginal progesterone treat-
ment (90-mg vaginal gel or 200-mg micronized vaginal soft cap-
sules) is a cost-effective model for the prevention of preterm birth.”
• “In cases in which a transvaginal ultrasound is not available, other 
devices may be used as a screening tool to measure objectively and 
reliably the cervical length.”
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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The aim of the present review is to discuss the rationale for these 
recommendations, their likely impact, and whether they should be 
updated in the light of new evidence.
2  | ROLE OF PROGESTERONE IN 
PREGNANCY MAINTENANCE
Progesterone clearly plays a role in the maintenance of pregnancy. 
Circulating levels of progesterone rise during pregnancy: the major 
source (in humans) is the corpus luteum until approximately week 8 
of pregnancy, and the placenta thereafter. One of the major mecha-
nisms of progesterone action in maintaining pregnancy is inhibition of 
the contractions of the myometrium: research has demonstrated the 
relaxant effect of progesterone on myometrial strips in vitro.2
The importance of progesterone in maintaining human pregnancy in 
vivo has been demonstrated by studies administering receptor antagonists 
such as mifepristone (RU486). If administered in early pregnancy, mifepri-
stone increases uterine contractility in vivo,3 sensitizes the uterus to the 
pro-contractile effects of prostaglandins, and acts as an effective abortifa-
cient (although it is much more effective when combined with prostaglan-
din).4 In late pregnancy, mifepristone can be used to induce labor, although 
its safety in the absence of intrauterine fetal death is unclear.5 Lastly, the 
withdrawal of progesterone is probably involved in the spontaneous initi-
ation of labor at term. In many animal species, progesterone withdrawal 
is caused by a decrease in circulating levels of progesterone. In humans, 
progesterone levels are maintained until the end of pregnancy and in labor, 
but complex alterations in progesterone receptor activity result in a decline 
in progesterone receptor signaling at the time of labor onset (reviewed 
by Menon et al.6).
So, what is the evidence on which the FIGO recommendations for pro-
gesterone prophylaxis in women with a short cervix are based? To address 
this question, it is necessary to consider the efficacy of progesterone, the 
impact of such a strategy on a population basis, and the long-term benefits 
and harmful effects of progesterone treatment in pregnancy.
3  | EFFICACY OF PROGESTERONE FOR 
PRETERM BIRTH PREVENTION
The most recent Cochrane review on progesterone for the prevention 
of preterm birth (published in 2013) examined evidence on the use of 
any progestogen for women at risk of preterm birth either because of a 
previous preterm birth or because of a short cervix.7 Although the two 
F I G U R E  1   Cervical length measurement by ultrasound examination. The distance from A to B is the interval that should be reported for 
cervical length. The length of the “funneled” cervix should not be included.
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risk categories were examined separately, all progestogens were con-
sidered together. For women with a previous preterm birth, the review 
suggested that progestogens reduce the risk of preterm birth before 34 
gestational weeks [relative risk (RR), 0.31; 95% confidence interval (CI), 
0.14–0.69], reduce perinatal mortality (RR, 0.50; 95% CI, 0.33–0.75), 
reduce the incidence of low birthweight (<2500 g; RR, 0.58; 95% CI, 
0.42–0.79), and reduce neonatal death (RR, 0.45; 95% CI, 0.27–0.76). 
The sample size for the data on perinatal or neonatal death was 1453, 
whereas that for preterm birth before 34 weeks was 602.
For women with cervical shortening the review found that, among 
the above outcomes, only preterm birth before 34 weeks was reduced 
by progestogen (RR, 0.64; 95% CI, 0.45–0.90).7 Although there was a 
trend toward a reduction in perinatal mortality, a reduction in birth-
weight <2500 g, and a reduction in neonatal death, none of these 
effects was statistically significant [RR (95% CI): 0.74 (0.42–1.29), 0.92 
(0.78–1.09), and 0.55 (0.26–1.13), respectively].
Further analyses in the review found no differential effects in 
terms of route of administration, time of commencement of therapy, 
or dose of progesterone for the majority of outcomes examined.7 Note 
that a comparison of different routes of administration acts as a surro-
gate for different types of progestogen because natural progesterone 
is provided in formulations given vaginally, and the synthetic formula-
tion 17-hydroxyprogesterone caproate is given intramuscularly.
Importantly for clinicians and for pregnant women, the regu-
latory status of the different progestogen formulations given for 
preterm birth differs. Intramuscular 17-hydroxyprogesterone caproate 
(Makena) is licensed by the US Food and Drug Administration (FDA), 
but not the European Medicines Agency (EMA), to reduce the risk 
of preterm birth for women with a singleton pregnancy who have a 
history of singleton spontaneous preterm birth. The product license 
refers to a dose of 250 mg, administered intramuscularly once per 
week, starting between 16+0 and 20+6 gestational weeks, and con-
tinued until 37 weeks or delivery (whichever is earlier). Supporting 
evidence for the licensing of intramuscular 17-hydroxyprogesterone 
caproate were provided by the trial of Meis et al.8
Although the FDA provided a license, a component of approval 
was the requirement for a confirmatory trial.9 The subsequent mul-
ticenter, randomized, double-blind, placebo-controlled clinical trial 
(“PROLONG”) recruited women with a singleton pregnancy and a 
history of a previous singleton spontaneous preterm delivery for 
randomization to either 17-hydroxyprogesterone caproate (250 mg; 
1 mL; planned n=1138) or vehicle (planned n=569) given weekly from 
16+0 to 20+6 gestational weeks until 37 weeks or delivery (whichever 
is the earliest). The two co-primary efficacy endpoints were preterm 
birth before 35 gestational weeks and a composite index of neonatal 
morbidity and mortality.
The results of the PROLONG study were published in October 
2019.10 The planned sample size was achieved, with 1130 women in 
the 17-hydroxyprogesterone caproate group and 578 women in the 
placebo group. There was no significant difference in either preterm 
birth before 35 weeks (11.0% vs 11.5%; RR, 0.95; 95% CI, 0.71–1.26]) 
or neonatal morbidity index (5.6% vs 5.0%; RR, 1.12; 95% CI, 0.68–
1.61) between the two groups.
Commentators have had a mixed reaction to publication of the 
PROLONG study. The FDA advisory committee has suggested that 17-
hydroxyprogesterone acetate should be withdrawn from the market for 
the prevention of preterm delivery, although this decision has not yet 
been finalized. The American College of Obstetricians and Gynecologists 
(ACOG) and the Society for Maternal and Fetal Medicine (SMFM) have 
both noted that women enrolled in the PROLONG trial were at lower risk 
for preterm birth as compared with those in the trial of Meis et al.8: they 
were less likely to be black or to smoke, and fewer had a previous preterm 
birth or other risk factors for preterm birth. In view of these discrepancies, 
ACOG continues to endorse the use of 17-hydroxyprogesterone acetate 
for the prevention of preterm birth, whereas SMFM endorses use for 
women with a risk profile similar to those in the trial of Meis et al.8
In contrast to 17-hydroxyprogesterone caproate, vaginal progester-
one is not licensed for preventing preterm birth in the United States. 
A submission to the FDA was prepared from data generated by a large 
randomized trial conducted in the United States and elsewhere.11 
In that study, 465 women with a singleton pregnancy, a short cervix 
(10–20 mm) at 19+0 to 23+6 gestational weeks were randomized either 
to vaginal progesterone (90 mg) or placebo. The primary outcome was 
delivery before 33 weeks, and 235 and 223 women were available for 
follow-up in each group. The progesterone group showed a significant 
reduction in the rate of preterm birth before 33 gestational weeks (RR, 
0.55; 95% CI, 0.33–0.92) and in neonatal outcome as a composite of 
adverse events (RR, 95% CI 0.57, 0.33–0.99). Among the individual com-
ponents of neonatal outcome, only a reduction in respiratory distress 
syndrome was statistically significant (RR, 0.39; 95% CI, 0.17–0.92).
Having reviewed the data from that study, the FDA chose not to 
provide a license for vaginal progesterone for preterm birth preven-
tion. The FDA notes accompanying their decision state: “the statistical 
test used by the ‘applicant’ was inappropriate because of insufficient 
sample size in each strata and inconsistent treatment effects within 
strata,” that “the first dose, maternal age, cervical length, body mass 
index, and race differed notably by region,” and that “after adjusting for 
these covariates, the effect of progesterone in reducing preterm birth 
was not statistically significant”.12
Two large studies published since the Cochrane review in 2013 did 
not find a positive effect of progesterone in preventing preterm birth. 
For women at high risk of preterm labor, the OPPTIMUM study13 con-
ducted by myself and co-workers tested whether, relative to a pla-
cebo, prophylactic vaginal natural progesterone (200 mg daily) from 
22 to 34 gestational weeks would:
• improve obstetric outcome by lengthening pregnancy and thus 
reducing the incidence of preterm delivery (before 34 weeks);
• improve neonatal outcome by reducing a composite of death and 
major morbidity;
• lead to improved childhood cognitive and neurosensory outcomes 
at 2 years.
The double-masked placebo-controlled randomized OPPTIMUM 
trial was conducted among 1228 women at high risk of preterm birth 
at 65 UK National Health Service (NHS) hospitals and one Swedish 
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hospital between February 2009 and April 2013.13 The study was reg-
istered (ISRCTN14568373), and the protocol was published.14 Eligibility 
for the study (high risk for preterm birth) was conferred by a positive fetal 
fibronectin test performed between 22+0 and 24+0 gestational weeks, 
combined with a history in a previous pregnancy of any of the following: 
preterm birth, second-trimester loss, premature fetal membrane rup-
ture, or a cervical procedure to treat an abnormal smear test. In addition, 
women with a history of a previous spontaneous preterm birth before 
34+0 weeks and those with a cervical length of 25 mm in the index preg-
nancy were eligible regardless of the fetal fibronectin test result.
The odds ratio (OR), 95% CI, and P values for the three primary out-
comes are summarized in Table 1. Vaginal progesterone was found to 
have no significant effect on any of the primary outcomes. Moreover, a 
subgroup analysis of women with a short cervix showed no significant 
interaction between cervical length and outcome—in other words, 
women with a short cervix did not respond better (or worse) to pro-
gesterone as compared with any other women in the study.
Subsequently, the PROGRESS study15 randomized 787 women at 
high risk of preterm birth because of a spontaneous previous preterm 
birth to vaginal progesterone (100 mg daily) or placebo. The primary 
outcome, incidence of respiratory distress syndrome, was similar in both 
groups: 10.5% (42/402) in the progesterone group and 10.6% (41/388) 
in the placebo group (adjusted RR, 0.98; 95% CI, 0.64–1.49; P=0.912).
Thus, there are clearly conflicting data about the efficacy of proges-
terone for preterm birth prevention.16,17 Some meta-analyses, focusing 
exclusively on women with a short cervix, have suggested that proges-
terone is effective in this situation,18 whereas others focusing on pro-
spectively registered studies found no difference between the groups.19
To address this controversy, the Patient-Centered Outcomes 
Research Initiative (PCORI) has commissioned a prospective, inde-
pendent comprehensive, high-quality, individual patient data meta-
analysis on the efficacy of progesterone for preterm birth prevention. 
Researchers from all studies evaluating the efficacy of progestogens for 
preterm birth prevention have been invited to submit their data. The 
results are expected in early 2020, and it is likely that this project will 
give the most authoritative estimates of the efficacy of progesterone for 
preventing preterm birth and its consequences for women at high risk.
4  | LIKELY IMPACT OF PROGESTOGENS 
ON PRETERM BIRTH PREVENTION
Many groups have evaluated the cost-effectiveness of routine cervi-
cal length scanning to identify women with a short cervix, combined 
with prescribing progesterone for preterm birth prevention.20–22 Most 
of these studies have evaluated populations in the United States, and 
a majority of the studies show that such a strategy is “cost effective”. 
The assumptions made in one of these studies20 are summarized 
in Table 2.
The overall analysis suggested that a policy of routine cervical 
length scanning (estimated to cost approximately US $3.5 million 
annually for pregnant women without a previous preterm birth) 
combined with progesterone prophylaxis for 0.85% of women with 
a short cervix would be cost-effective in the United States. It would 
require 2.19 million vaginal sonograms, and the prescription of vagi-
nal progesterone for 11 027 women annually; however, there would 
be 913 fewer preterm births and 63 fewer neonatal deaths. The 
total cost would be US $52 million annually. Given the costs accru-
ing from adverse outcomes due to prematurity, the “no screen” 
option was most expensive. Risk-based screening was the least 
expensive option, but universal screening was most cost-effective, 
with an incremental cost-effectiveness ratio of US $21 144 per 
quality-adjusted life year.20 Another study has also demonstrated 
the cost-effectiveness of routine or risk-based screening,21 whereas 
others have suggested that routine measurement is not worth-
while in populations where the risk of spontaneous preterm birth 
is low.23,24
Regardless of its cost-effectiveness, the impact of universal 
cervical length screening on the rate of preterm births is trivial in 
the context of the overall preterm birth rate. In 2014, there were 
381 659 preterm births in the United States; thus, prevention of 913 
births would reduce the rate of preterm birth from 9.57% to 9.55%. 
Performing a similar analysis in France, Rozenberg has described this 
as the inverse of the Pareto principle—in other words, a large amount 
of effort for a small gain.25
There are other challenges in providing universal cervical length 
screening. The sonogram “cost” of US $73.47 described above proba-
bly does not include training, quality-control programs, or equipment. 
In addition, without extensive training of additional providers, there 
will be insufficient availability of cervical length scanning to perform 
this analysis on a population basis. Furthermore, reproducibility is lim-
ited even when experienced observers perform measurements under 
standardized conditions.26 Others have suggested that universal 
treatment of all pregnant women with progestogen is the most cost-
effective strategy,27 although this assumes that the reduction in RR 
of preterm birth is the same across all risk factors and all countries: 
formal testing in well-designed clinical trials is required before we can 
be confident that this is the case.
T A B L E  1   Outcomes from the OPPTIMUM study.a
Primary outcome Placebo Progesterone aOR (95% CI) Adjusted P value
Fetal death or delivery <34 wk 108/597 (18.1) 96/600 (16.0) 0.86 (0.61–1.22) 0.67
Neonatal morbidity or death 60/587 (10.2) 39/589 (6.6) 0.62 (0.38–1.03) 0.07
Cognitive composite score at 2 y 97.7 ± 17.5 97.3 ± 17.9 –0.48 (–2.77 to 1.81) 0.68
Abbreviation: aOR, adjusted odds ratio; CI, confidence interval.
aTaken from Ref. 13. Values are given as number/sample number (percentage) or mean ± SD.
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5  | LONG‐TERM RISKS AND HARMS OF 
PROGESTERONE PROPHYLAXIS
Clinicians and pregnant women wishing to use progesterone to pre-
vent preterm birth need to be aware of the long-term risks and ben-
efits. The primary rationale for preventing preterm birth is to avert 
adverse consequences for the newborn. Worldwide, 15 million pre-
term births per annum result in around 2000 neonatal deaths, and 
neurodevelopmental disability in nearly 1 million survivors.28 Data 
from Scotland show a reduced requirement for additional support 
in school for every extra week of gestational age at birth from 24 
to 41 weeks.29 It is often assumed, therefore, that delaying preterm 
birth by several weeks will improve outcome. This assumption may 
not be true, given the role of intrauterine infection in the initia-
tion of many preterm births,30 an event that can have a deleterious 
effect on fetal organs, particularly the brain and lungs.31 Long-term 
follow-up of the neonate may be needed to determine the true 
risks and benefits of any intervention on neurodevelopmental and 
other outcomes.
A good example of this is the ORACLE II randomized trial of antibi-
otics to prevent preterm birth among women presenting with signs and 
symptoms of preterm labor, but with intact fetal membranes. Although 
there were no major differences in outcome in the short term (and 
no significant impact of antibiotics on gestational age),32 at 7 years of 
age, children who had been exposed in utero to either erythromycin or 
co-amoxiclav had increased rates of cerebral palsy as compared with 
those given placebo.33 There was also evidence of a stronger adverse 
effect among children who were exposed to both agents.
Regarding singleton pregnancy, only two studies have examined 
the long-term effect of progestogens. The follow-up to the study of 
17-hydroxyprogesterone caproate by Meis et al.8 showed no differ-
ence in any of the developmental domains of children assessed at 
approximately 2 years with approximately 80% available for assess-
ment.34 A childhood developmental assessment was one of the 
three primary outcomes in the OPPTIMUM study, which showed 
no difference in cognitive composite score between the active and 
the placebo groups.13 There was a trend toward higher moderate-
to-severe neurodevelopmental disability in the progesterone group 
(47/379, 12.4%) as compared with the placebo group (35/403, 
8.7%), but the difference was not significant (OR, 1.48; 95% CI, 
0.98–2.33; P=0.087).
6  | CONCLUSION
The National Institute of Clinical Excellence in the United Kingdom,35 
FIGO, and the SMFM in the United States all recommend the use 
of progestogens for women at high risk of preterm birth. The latter 
advises that women between 20 and 366 gestational weeks receive 
17-hydroxyprogesterone caproate (250 mg intramuscularly weekly) 
starting at 16–20 weeks until 36 weeks or delivery for women with a 
singleton gestation and a history of prior spontaneous preterm birth.36 
The two former organizations endorse the use of vaginal progesterone 
for women with a short cervix.
As discussed in this review, however, the evidence on efficacy 
for those at risk of preterm birth, impact on preterm birth rates, 
and long-term effects for the baby of implementing these recom-
mendations remains inconclusive. Clinicians and pregnant women 
can look forward to some resolution of the conflicting views on 
efficacy once the PCORI-funded individual patient data meta-anal-
ysis is published. Recommendations should be updated once the 
full details of the PCORI individual patient data meta-analysis is in 
the public domain.
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T A B L E  2   Assumptions around cost-effectiveness calculations 






Prevalence of CL ≤20 mm in low-risk population, % 0.85 
(0.46–3.5)
RR of delivery at <35 wk with vaginal progesterone 0.6 (0.36–0.9)
Costs
Cost of transvaginal sonogram, $ 73.47 (50.00–
340.00)
Vaginal progesterone, $ 216 
(100–450)
Abbreviations: CI, confidence interval; CL, confidence limit; RR, risk ratio.
aTaken from Ref.20.
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